For 87 years, our industry had to operate under an uncomfortable truth: over 90% of cancer drugs that "cure" mice routinely fail patients in clinical trials. In 2022, the FDA Modernization Act 2.0 took the first historic step, lifting the animal testing mandate that had governed drug development since 1938. Then came the seismic shifts of 2025: in April, FDA launched a roadmap to phase out animal testing over the next 3-5 years and invited New Approach Methodologies (NAMs) data in INDs immediately. In July, NIH announced it would stop issuing new funding announcements focused exclusively on animal models, widening calls to prioritize human-relevant approaches. The policy infrastructure that propped up mouse models for nearly a century collapsed in months. This panel, led by industry trailblazers, will bring to light key differences among the types of NAMs, actionable strategies for adoption, avenues for making these accessible even to smaller biopharma companies, and the imperative for coming together to accelerate breakthroughs and blockbusters in oncology. Attendees will gain insights that help bridge the gap from drug discovery to successful partnerships and licensing.